Status:
ENROLLING_BY_INVITATION
Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Lead Sponsor:
The University of Hong Kong
Conditions:
Cannabis Use
Neurocognitive Dysfunction
Eligibility:
All Genders
16-60 years
Brief Summary
Most of the studies assessing Cannabis Use Disorder (CUD) and neurocognitive functions are cross-sectional without examining the longitudinal changes in neurocognitive function at a within-subject lev...
Eligibility Criteria
Inclusion
- Age: 16 - 60 years old at the time of enrolment
- Able to read and communicate in English and/or Chinese
- Able to give informed consent
- Using cannabis or marijuana as the primary psychoactive substance of abuse
- Repeated and Active cannabis users as defined by Structured Clinical Interview for DSM-5 Disorders
Exclusion
- Age \<16 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed with other Substance Related Disorders, except for Tobacco Use Disorders due to the known frequent comorbid use for cannabis users (12)
- Currently taking regular prescribed psychiatric medications, including antipsychotics, antidepressants, mood stabilizers, anti-epileptics, benzodiazepines, hypnotics, and anti-cholinergic medications.
- Had been diagnosed with DSM-5 disorders, other than Cannabis Use and related disorders
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT04373525
Start Date
November 1 2020
End Date
August 31 2025
Last Update
July 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong, 000000